Purchase this article with an account.
L. Ly, M. Sluijter, M. Kouch-el Filali, G. P. M. Luyten, R. Offringa, M. J. Jager, M. J. B. van Stipdonk; Gp100 Peptide Vaccine for Intraocular Melanoma. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4755.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Melanoma cells express the protein gp100. The effectiveness of immunotherapy based on gp100 peptide vaccination was tested in a well established intraocular B16F10 eye melanoma model.
C57Bl/6 mice were adoptively transferred with T cell receptor-transgenic, human gp100 specific CD8+ T lymphocytes (pmel). Mice received a total of 4 subcutaneous injections with gp100 peptide, starting 2 weeks before tumor inoculation. Immunostimulatory cream containing the TLR-7 ligand Imiquimod (AldaraTM) was applied at the injection site. Some mice were additionally treated with IL-2 i.v. One week after the second vaccination, B16F10 melanoma cells were inoculated in the anterior chamber of the mouse eye. Tumor growth was followed with binocular microscopy and scored semi-quantitatively.
Tumor growth in the group treated with adoptive transfer of CD8+ cells, gp100 vaccination and Aldara showed a delay in tumor growth. Adding IL-2 intravenously one week before tumor inoculation prevented growth of a B16F10 tumor in the anterior chamber of the eye.
Immunotherapy consisting of pmel cells, gp100 peptide vaccination and AldaraTM cream delays tumor growth in the eye. Additional treatment with IL-2 induces complete protection against tumor growth of a B16F10 tumor in the anterior chamber of the eye of a C57/Bl6 mouse.
This PDF is available to Subscribers Only